Skip to main content
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2002 Nov;61(Suppl 2):ii88–ii89. doi: 10.1136/ard.61.suppl_2.ii88

Pharmacovigilance: towards a better understanding of the benefit to risk ratio

L Simon
PMCID: PMC1766711  PMID: 12379634

Full Text

The Full Text of this article is available as a PDF (88.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Edlavitch S. A. Postmarketing surveillance methodologies. Drug Intell Clin Pharm. 1988 Jan;22(1):68–78. doi: 10.1177/106002808802200117. [DOI] [PubMed] [Google Scholar]
  2. Fletcher A. P. Spontaneous adverse drug reaction reporting vs event monitoring: a comparison. J R Soc Med. 1991 Jun;84(6):341–344. doi: 10.1177/014107689108400612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Leiper J. M., Lawson D. H. Why do doctors not report adverse drug reactions? Neth J Med. 1985;28(12):546–550. [PubMed] [Google Scholar]
  4. Shapiro S. The epidemiological evaluation of drugs. Acta Med Scand Suppl. 1984;683:23–27. doi: 10.1111/j.0954-6820.1984.tb08710.x. [DOI] [PubMed] [Google Scholar]
  5. Strom B. L., Melmon K. L., Miettinen O. S. Postmarketing studies of drug efficacy. Arch Intern Med. 1985 Oct;145(10):1791–1794. [PubMed] [Google Scholar]
  6. Strom B. L. Overview of different logistical approaches to postmarketing surveillance. J Rheumatol Suppl. 1988 Oct;17:9–13. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES